Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy

This is an interventional treatment trial for Colorectal Cancer focused on measuring metastatic, colon, rectum, combination, chemotherapy Read More

Inclusion Criteria:

• Metastatic CRC that has progressed following first-line therapy.
• Measurable disease (Response Evaluation Criteria in Solid Tumors [RECIST], Version 1.0.
• Male or female ≥ 18 years of age.
• Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
• Resolution of any toxic effects of prior therapy (except alopecia) to NCI CTCAE, Version 3.0, grade ≤ 1.

• Adequate organ and bone marrow function as evidenced by:

  • Hemoglobin ≥ 9 g/dL (transfusion and/or growth factor support allowed)
  • Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L
  • Platelet count ≥ 100 x 10^9/L
  • Serum creatinine ≤ 1.5 x the upper limit of normal (ULN) or creatinine clearance ≥ 60 mL/min
  • Aspartate aminotransferase (AST) and alkaline phosphatase ≤ 2.5 x ULN in participants with no liver metastasis and ≤ 5.0 x ULN in participants with liver metastasis
  • Total bilirubin ≤ 1.5 x ULN
• Women of childbearing potential must be willing to consent to using effective contraception (eg, hormonal contraceptives, bilateral tubal ligation, barrier with spermicide, intrauterine device) while on treatment and for at least 3 months thereafter. Men who are the partner of a woman of childbearing potential must be willing to consent to using effective contraception (eg, vasectomy or barrier with spermicide) while on treatment and for 3 months thereafter.
• All female participants of childbearing potential must have a negative pregnancy test (serum or urine) result before initiating study treatment.
• Participants must be fully informed about their illness and the investigational nature of the study protocol (including foreseeable risks and possible side effects) and must sign and date an Independent Ethics Committee (IEC)- or Institutional Review Board (IRB)-approved informed consent form (ICF) (including HIPAA authorization, if applicable) before performance of any study-specific procedures or tests.
• Participants must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion Criteria:

• First-line treatment with an irinotecan-based regimen (eg, FOLFIRI).
• Anticipation of need for a major surgical procedure or radiation therapy (RT) during the study.
• Treatment with chemotherapy, other thiazolidinediones (TZD), RT, surgery, immunotherapy, biological therapy, or any investigational anticancer agent within 4 weeks before start of study treatment.

• History of any of the following conditions within 6 months before initiating study treatment:

  • Diabetes mellitus requiring treatment with insulin or TZD agents
  • Myocardial infarction with significant impairment of cardiac function (eg, ejection fraction ≤ 50%)
  • Severe/unstable angina pectoris
  • Coronary/peripheral artery bypass graft
  • New York Heart Association (NYHA) class III or IV congestive heart failure
  • Malabsorption syndrome, chronic diarrhea (lasting > 4 weeks), inflammatory bowel disease, or partial bowel obstruction.
• Participants with clinically active brain metastases (defined as untreated, symptomatic, or requiring therapy with steroids or anticonvulsants to control associated symptoms); uncontrolled seizure disorder; spinal cord compression; or carcinomatous meningitis. Participants with treated brain metastasis will be included in the study if they have recovered from the acute, toxic effects of RT. A minimum of 15 days must have elapsed between the end of RT and enrollment into the study.
• History of malignancy other than CRC, unless there is an expectation that the malignancy has been cured, and tumor-specific treatment for the malignancy has not been administered within the previous 5 years.
• Clinically significant, severe, active infection requiring IV antibiotic or antiviral agents.
• Pericardial or pleural effusion (eg, requiring drainage) or pericardial involvement with the tumor. Participants with minimal pleural effusion may be eligible upon request by Investigator and approval by Sponsor.
• Need for concomitant use of other TZD agents during the study.
• Previous administration of CS-7017.
• Pregnant or breast feeding.
• Known to be homozygous for the UGT1A1*28 allele.
• Known history of severe hypersensitivity reactions to any of the components of CS-7017, irinotecan, leucovorin, or 5-FU.
• Serious intercurrent medical or psychiatric illnesses or any other conditions that in the opinion of the Investigator would impair the ability to give informed consent or unacceptably reduce protocol compliance or safety of the study treatment.